Allscripts (MDRX) Misses Q4 EPS by 1c, Offers Guidnce
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Reiterates Buy on Allscripts (MDRX) Following 4Q
February 17, 2017 8:26 AM ESTJefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following 4Q earnings report. MDRX reported EPS of $0.14, which compares to $0.15 for consensus. Downside was driven by higher SG&A, partially offset by better revenue, a higher gross margin and... More
Allscripts (MDRX) PT Raised to $13 at Cantor Fitzgerald Following In-Line 4Q Results
February 17, 2017 7:22 AM ESTCantor Fitzgerald analyst Steven Halper reiterates Neutral rating and raises price target on Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) to $13 (from $12), suggesting shares remain fairly valued, as the company reported 2016 fourth quarter results in-line with estimates, while 2017 guidance was also in-line with... More
